Geldanamycin Enhances Retrograde Transport of Shiga Toxin in HEp-2 Cells

PLoS One. 2015 May 27;10(5):e0129214. doi: 10.1371/journal.pone.0129214. eCollection 2015.

Abstract

The heat shock protein 90 (Hsp90) inhibitor geldanamycin (GA) has been shown to alter endosomal sorting, diverting cargo destined for the recycling pathway into the lysosomal pathway. Here we investigated whether GA also affects the sorting of cargo into the retrograde pathway from endosomes to the Golgi apparatus. As a model cargo we used the bacterial toxin Shiga toxin, which exploits the retrograde pathway as an entry route to the cytosol. Indeed, GA treatment of HEp-2 cells strongly increased the Shiga toxin transport to the Golgi apparatus. The enhanced Golgi transport was not due to increased endocytic uptake of the toxin or perturbed recycling, suggesting that GA selectively enhances endosomal sorting into the retrograde pathway. Moreover, GA activated p38 and both inhibitors of p38 or its substrate MK2 partially counteracted the GA-induced increase in Shiga toxin transport. Thus, our data suggest that GA-induced p38 and MK2 activation participate in the increased Shiga toxin transport to the Golgi apparatus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Toxins / metabolism
  • Benzoquinones / pharmacology*
  • Biological Transport / drug effects*
  • Cell Line, Tumor
  • Cytosol / drug effects
  • Cytosol / metabolism
  • Endocytosis / drug effects
  • Endosomes / drug effects
  • Endosomes / metabolism
  • Golgi Apparatus / drug effects
  • Golgi Apparatus / metabolism
  • Humans
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Lactams, Macrocyclic / pharmacology*
  • Protein Serine-Threonine Kinases / metabolism
  • Protein Transport / drug effects*
  • Shiga Toxin / metabolism*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Bacterial Toxins
  • Benzoquinones
  • Intracellular Signaling Peptides and Proteins
  • Lactams, Macrocyclic
  • Shiga Toxin
  • MAP-kinase-activated kinase 2
  • Protein Serine-Threonine Kinases
  • p38 Mitogen-Activated Protein Kinases
  • geldanamycin

Grants and funding

This work was supported by grants from the Norwegian Cancer Society, the Research Council of Norway through its Centres of Excellence funding scheme, project number 179571, the South-Eastern Norway Regional Health Authority and the University of Oslo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.